This video is a virtual investor conference presentation by NervGen Pharma Corp., a clinical-stage biotechnology company focused on developing treatments for nervous system damage. The presentation centers on their lead product candidate, NVG291, and its progress in clinical trials for spinal cord injury, along with updates on their pipeline and future plans.
NervGen's goal is to get NVG291 to patients as quickly as possible and their intent is to launch the product themselves. They have the internal resources to conduct Phase 3 trials. However, they are open to partnering with larger companies that could accelerate the process and get the product to market sooner if a suitable opportunity arises. The primary constraint is funding for Phase 3 trials; they will need additional cash to advance to that stage.
